Assessment of Sensitivity Pattern of Tuberculosis in Response to 1st Line Anti Tuberculosis Drugs.

Ammar Shafiq, Ali Mustafa, Bakht Bilal

Abstract


Objective: The main aim of this study was to find the sensitivity pattern of tuberculosis to 1st line of antibiotics.

Place and Duration of Study: This study was carried out in Pulmonology department of Mayo hospital Lahore in a duration of 10 months from March 2018 to December 2019.

Type of Study: Cross sectional.

Materials and Methods: Patients were selected without gender discrimination having age greater than 15 years. Exclusion criteria included the patients who had already used ATT. LJ medium was used for sputum analysis for six weeks. Sensitivity of Mycobacterium was analyzed to 1st line of antibiotics. 2 mcg of streptomycin, 100 mcg for pyrazinamide, 0.2 mcg for isoniazid, 5 mcg of ethambutol and 1 mcg of rifampicin were the standard dose of drugs which was used in LJ medium to check the sensitivity.

Results: A total of 115 cases were included in this study. Among these patients 72 (62.60%) were males. The mean age of patients was 35 years. In 36 (32.17%) of the cases drug resistance was seen and in some cases resistance was seen to more than 1 drug. Streptomycin was the most common drug to which Mycobacterium showed resistance and it included 19 (16.52%) of cases. Second most common involving 17 (14.78%) of cases was isoniazid. In 30 (26.08%) cases resistance was seen to only one drug. Only 2 cases showed resistance to three and four antibiotics.

Conclusion: Almost every third case is resistant to TB antibiotics and highest resistance is seen in case of streptomycin.


Keywords


ATT. Lowenstein Jensen medium, MTB

Full Text:

PDF

References


World Health Organization. Global Tuberculosis Report 2016. Geneva, Switzerland: World Health Organization; 2016. Available from: http://www.who.int/tb/publications/global_report/en/. [Last accessed 2017 Mar 02].

Rahman M, Kamal SM, Mohammed FR, Alam B, Ahasan HN. Anti-tuberculosis drug resistance pattern among different category of tuberculosis patients. J Med. 2009;10(2):45-7.

NTP. Programmatic management of drug resistant tuberculosis (PMDT) [internet]. 2014 [cited2016 Jul 20]. Available from: http://www.who.int/ tb/dots/mdr_tb_guidelines_ppt.pdf

Mahmoudi A, Iseman MD. Pitfalls in the care of patients with tuberculosis. JAMA. 1993;270(1):65-8.

Kandi S, Prasad SV, Sagar Reddy PN, Reddy VC, Laxmi R, Kopuu D, et al. Prevalence of multidrug resistance among re-treatment pulmonary tuberculosis cases in a tertiary care hospital, Hyderabad, India. Lung India. 2013;30(4): 277–9.

Haq M, Salam A, Bashir I. Prevalance of resistance to 1st line anti tubrerculosis drugs at Rahim Yar Khan. JSZMC. 2016;7(3):988-92.

Tayyab HM, Hashmi S, Subhani GM, Saddique MA, Sheikh I. Multidrug Resistant Tuberculosis in Punjab, Pakistan. APMC. 2014;8(1):88-96.

Nathavitharana RR, Cudahy PG, Schumacher SG, Steingart KR, Pai M, Denkinger CM, et al. Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: A systematic review and meta-analysis. Eur Respir J. 2017;49(1):1601075.

Bablishvili N, Tukvadze N, Avaliani Z, Blumberg HM, Kempker RR. A comparison of the Xpert ® MTB/RIF and GenoType ®MTBDRplus assays in Georgia. Int J Tuberc Lung Dis. 2015;19(6):676-8.

Theron G, Peter J, Meldau R, Khalfey H, Gina P, Matinyena B, et al. Accuracy and impact of Xpert MTB/RIF for the diagnosis of smear-negative or sputum-scarce tuberculosis using bronchoalveolar lavage fluid. Thorax. 2013;68(11):1043-51.

World Health Organizaton. Treatment of tuberculosis guidelines for national programmes. 4th et. Geneva; WHO; 2009.

Raveendran, R, Oberoi JK, Wattal C. Multidrug-resistant pulmonary and extra- pulmonary tuberculosis: a 13 years retrospective hospital-based analysis. Indian. Indian J Med Res. 2015;142(5):575-82.

Dusthackeer A, Sekar G, Chidambaram S, Kumar V, Mehta P, Swaminathan S. Drug resistance among extrapulmonary TB patients: Six years’ experience from a supranational reference laboratory. Indian. Indian J Med Res. 2015;142(5):568-74.

Lönnroth K, Migliori GB, Abubakar I, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J. 2015;45(4):928-52.

Gupta K, Nair D, Sharma P, Gupta A, Sen MK. Changing Trends in the Susceptibility Pattern of Mycobacterium tuberculosis Over a Decade from a Tertiary Care DOTS Centre Delhi. Mycobact Dis. 2016;6(2):211.

Diacon AH, van der Merwe L, Barnard M, et al. β-Lactams against Tuberculosis--New Trick for an Old Dog? N Engl J Med. 2016;375(4):393-4.

Mohammad AB, Iliyasu G, Habib AG. Prevalence and genetic determinant of drug-resistant tuberculosis among patients completing intensive phase of treatment in a tertiary referral center in Nigeria. Int J Mycobacteriol. 2017;6(1):47-51.

Maurya AK, Singh AK, Kumar M, Umrao J, Kant S, Nag VL, et al. Changing patterns and trends of multidrug-resistant tubeculosis at referral centre in Northern India: A 4-year experience. Indian J Med Microbiol. 2013;31(1):40-6.

Caminero JA, Scardigli A. Classification of antituberculosis drugs: a new proposal based on the most recent evidence. Eur Respir J. 2015;46(4):887-93.

Munir MK, Adnan M, Shabbir I, Rahat T, Rehman S. Therapeutic Outcome of Pulmonary Tuberculosis in Type-2 Diabetes Patients. APMC. 2018;12(2):98-102.

Khalid M, Hassan S, Saeed MS. Drug resistance pattern among AFB smear positive retreatment completed cases. Pak Med Res Council. 2015;21(1):5-8.

Almani SA, Memon NM, Qureshi AF. Drug resistant tuberculosis in Sindh. JCPSP. 2002;12(3):136-9.


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.